TD Asset Management Inc Cuts Stock Position in CVS Health Corporation $CVS

TD Asset Management Inc decreased its holdings in shares of CVS Health Corporation (NYSE:CVS) by 3.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 1,224,957 shares of the pharmacy operator’s stock after selling 38,412 shares during the period. TD Asset Management Inc’s holdings in CVS Health were worth $97,213,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of CVS Health by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock worth $9,579,508,000 after acquiring an additional 1,824,424 shares during the last quarter. Capital World Investors grew its stake in shares of CVS Health by 2.1% during the third quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock worth $5,155,380,000 after acquiring an additional 1,419,575 shares during the last quarter. State Street Corp grew its stake in shares of CVS Health by 0.3% during the third quarter. State Street Corp now owns 58,938,286 shares of the pharmacy operator’s stock worth $4,443,357,000 after acquiring an additional 149,701 shares during the last quarter. Capital International Investors grew its stake in shares of CVS Health by 1.1% during the third quarter. Capital International Investors now owns 26,692,203 shares of the pharmacy operator’s stock worth $2,012,347,000 after acquiring an additional 302,499 shares during the last quarter. Finally, Invesco Ltd. grew its stake in shares of CVS Health by 3.2% during the third quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock worth $1,831,454,000 after acquiring an additional 760,579 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Insider Buying and Selling

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Larry Robbins sold 1,983,538 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the transaction, the director directly owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. The trade was a 24.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,441,551 shares of company stock valued at $323,703,977 over the last three months. 0.85% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on CVS shares. Truist Financial boosted their price target on CVS Health from $102.00 to $108.00 and gave the stock a “buy” rating in a research note on Monday. The Goldman Sachs Group boosted their price target on CVS Health from $95.00 to $97.00 and gave the stock a “buy” rating in a research note on Thursday, February 12th. Leerink Partners restated an “outperform” rating and set a $98.00 price target on shares of CVS Health in a research note on Thursday, March 5th. Deutsche Bank Aktiengesellschaft upped their target price on CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, Wells Fargo & Company upped their target price on CVS Health from $102.00 to $103.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $99.88.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health was upgraded to Zacks Rank #2 (Buy), signaling improved earnings optimism and adding to the case for near-term upside. Article Title
• Positive Sentiment: Brokerage sentiment remains constructive, with reports noting an average recommendation of “Moderate Buy” for CVS, reinforcing investor confidence in the name. Article Title
• Positive Sentiment: Rallying health insurers such as Humana, UnitedHealth, and Cigna on hopes of softer medical cost trends is boosting sentiment across the sector and likely supporting CVS shares as well. Article Title
• Neutral Sentiment: CVS also highlighted community and behavioral-health initiatives, including senior affordable housing and expanded mental health access, which are positive for its long-term brand but unlikely to move the stock much in the short term. Article Title
• Neutral Sentiment: Broader market news, including futures weakness ahead of the jobs report, appears to be a macro backdrop rather than a CVS-specific driver. Article Title

CVS Health Price Performance

Shares of NYSE CVS opened at $94.84 on Friday. The business’s 50 day moving average price is $83.65 and its 200 day moving average price is $79.91. The firm has a market cap of $121.00 billion, a P/E ratio of 41.78, a P/E/G ratio of 0.89 and a beta of 0.62. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $98.43. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.CVS Health’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, sell-side analysts expect that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were issued a $0.665 dividend. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.8%. CVS Health’s payout ratio is presently 117.18%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.